Loading
A phase 1/2 trial of NECVAX-NEO1 in advanced solid tumours, run by NEC Bio B.V, active and no longer recruiting.
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT06631079 by NEC Bio B.V, with 20 participants enrolled, started 2024-10-07 and due to reach its primary completion in 2026-07-31. Interventions recorded: NECVAX-NEO1.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PD-L1, PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/